Development and Validation of a Dual-Language (English and Malay) Needs Assessment Tool for Breast Cancer (NeAT-BC).
Asia
breast cancer
development
needs assessment
questionnaire
validation
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
09 Jan 2023
09 Jan 2023
Historique:
received:
03
11
2022
revised:
16
12
2022
accepted:
05
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Background: Needs assessment tools may be used to guide the optimisation of cancer survivorship services. We sought to develop and validate a dual-language needs assessment tool for women with breast cancer. Methods: The study comprised two phases; (I) co-design, and (II) psychometric testing. In Phase I, items were generated based on focus group discussions with patients and a literature review. These items were then translated into the Malay language. Content and face validation were undertaken with an expert panel. In phase II, 315 Malaysian women living with breast cancer were recruited. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were conducted to determine construct validity and reliability. Criterion validity was assessed using the EORTC QLQ-C30 questionnaire. Results: We co-designed and validated a 48-item dual-language needs assessment tool for breast cancer (NeAT-BC). Five underlying constructs were revealed in the EFA: (1) emotional support, (2) social and intimate relationships, (3) hospital appointments, (4) personal care and health, and (5) information and services. The NeAT-BC demonstrated good reliability across all constructs (Cronbach’s alpha: 0.90 to 0.96). CFA also demonstrated acceptable convergent and divergent validity, composite reliability ≥ 0.87, and Heterotrait−Monotrait index < 0.85 for all constructs. Criterion validity was established given the significant negative correlation between overall needs and quality of life (r = −0.14; p = 0.02). The NeAT-BC took approximately 25 min to be completed and could be interviewer-administered or self-administered. Conclusion: The utilization of the NeAT-BC is expected to guide establishment of evidence-based cancer survivorship services in Malaysia, with wider potentials for adoption in other multi-ethnic and/or low-and-middle income settings.
Identifiants
pubmed: 36673050
pii: diagnostics13020241
doi: 10.3390/diagnostics13020241
pmc: PMC9858119
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Higher Education
ID : IIRG006C-19HWB
Organisme : Pfizer Malaysia
ID : UPUM/2019-MED.316
Références
Support Care Cancer. 2007 Oct;15(10):1125-44
pubmed: 17235503
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Curr Opin Oncol. 2014 Jul;26(4):372-9
pubmed: 24825016
J Pers Assess. 2016;98(3):223-37
pubmed: 26514921
Asia Pac J Oncol Nurs. 2020 Sep 14;7(4):375-381
pubmed: 33062834
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Support Care Cancer. 2014 Apr;22(4):1071-9
pubmed: 24292016
JCO Oncol Pract. 2021 Apr;17(4):e548-e555
pubmed: 32986532
Oncologist. 2020 Jun;25(6):497-504
pubmed: 31922332
J Cancer Surviv. 2021 Oct;15(5):706-712
pubmed: 33094415
Ochsner J. 2000 Jan;2(1):5-9
pubmed: 21765654
Support Care Cancer. 2021 Oct;29(10):5811-5819
pubmed: 33742239
J Clin Diagn Res. 2016 Oct;10(10):XC06-XC10
pubmed: 27891441
Psychooncology. 2018 Sep;27(9):2172-2179
pubmed: 29856903
Psychooncology. 2013 Jan;22(1):125-32
pubmed: 21956765
Psychooncology. 2007 Sep;16(9):796-804
pubmed: 17177268
Breast Cancer Res Treat. 2011 Nov;130(2):531-41
pubmed: 21617919
Chronic Dis Transl Med. 2018 Jul 07;4(3):164-175
pubmed: 30276363
Support Care Cancer. 2011 Dec;19(12):1957-68
pubmed: 21076926
Health Qual Life Outcomes. 2015 Dec 30;13:205
pubmed: 26715073
Yonsei Med J. 2012 Jan;53(1):118-25
pubmed: 22187241
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Psychooncology. 2020 Mar;29(3):539-549
pubmed: 31785043
Value Health. 2019 Feb;22(2):225-230
pubmed: 30711068
Acta Oncol. 2013 Feb;52(2):391-9
pubmed: 23244672
J Eval Clin Pract. 2019 Oct;25(5):889-895
pubmed: 30773748
Eur J Cancer Care (Engl). 2022 Jan;31(1):e13525
pubmed: 34729855
J Eval Clin Pract. 2009 Aug;15(4):602-6
pubmed: 19522727
J Cancer Surviv. 2022 Oct;16(5):960-975
pubmed: 34363187
Ecancermedicalscience. 2022 Sep 26;16:1449
pubmed: 36405936
Pharm Pract (Granada). 2019 Jan-Mar;17(1):1397
pubmed: 31015879
Lancet. 2011 Mar 5;377(9768):863-73
pubmed: 21269682
Can Oncol Nurs J. 2008 Winter;18(1):6-24
pubmed: 18512565
Disabil Rehabil. 2019 Dec;41(26):3151-3156
pubmed: 30052478
Eur J Oncol Nurs. 2020 Oct;48:101824
pubmed: 32942232
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
PLoS One. 2013 May 31;8(5):e65099
pubmed: 23741467
Aust N Z J Public Health. 2000 Apr;24(2):166-73
pubmed: 10790936
J Adv Nurs. 2001 Jun;34(6):760-71
pubmed: 11422546
J Adv Nurs. 1997 Jun;25(6):1175-83
pubmed: 9181414
PLoS One. 2019 Jan 8;14(1):e0210242
pubmed: 30620770
Cancer. 2015 Feb 15;121(4):623-30
pubmed: 25581252